Global Cancer Immunotherapy Market Will Exceed $216,792.7

Burlingame, January 23, 2023 (GLOBE NEWSWIRE) — According to Coherent Market Insights, Global Cancer Immunotherapy Market is rated at US$ 102,095.5 million at the 2022 and is expected to present a CAGR in 9.9% during the forecast period (2022-2030).

Analyst views:

The growth of cancer immunotherapy market may be hampered by the presence of alternative cancer treatment methods such as CAR T cell therapy, oncolytic virus therapy, cancer vaccine, acupuncture, yoga and others. For example, data published on March 21, 2022, by the National Cancer Institute, stated that there are different types of complementary and alternative medicines to treat or manage cancer, such as mind-body therapies, biobased practices, manipulative and body practices, energy healing and others.

Key trends and analysis of the global Immunotherapy for Cancer market:

The increasing adoption of inorganic strategies such as acquisitions among major market players to increase their product portfolio and market presence is expected to drive the growth of the market in the forecast period. For example, in August 2021, Pfizer, a pharmaceutical company, announced the acquisition of Trillium, a clinical-stage immuno-oncology company, to strengthen Pfizer’s next-generation immunotherapeutic research pipeline for hematologic malignancies.

Conductor:

Increased prevalence of cancer

The rising global prevalence of cancer is expected to drive market growth during the forecast period. For example, data published in March 2021 in Globocan stated that globally there were approximately 2,261,419 cases of breast cancer and 1,931,590 cases of colorectal cancer in 2020.

Increased adoption of organic strategies such as product approval

Increased adoption of strategies such as product approvals by regulatory bodies is expected to drive market growth over the forecast period. For example, on February 28, 2022, Janssen Pharmaceutical Company announced that the US Food and Drug Administration (FDA) had approved CARVYKTI, which is a CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma.

Request sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/5274

to containts:

Cancer treatment side effects

Cancer treatment side effects are expected to impede the growth of the cancer immunotherapy market. For example, side effects of cancer immunotherapy include arthritis, hypopituitarism, hypothyroidism, muscle pain, hepatitis, type 1 diabetes, neuropathy, paralysis, meningitis or encephalitis, and others.

Market tendencies:

Increased adoption of strategies such as product approval

Increased adoption of organic strategies such as product approvals by regulatory bodies is expected to drive market growth over the forecast period. For example, on January 20, 2022, Palleon Pharmaceuticals, a pioneering company in the field of glycoimmunology to treat cancer and inflammatory diseases, announced that the U.S. Food and Drug Administration had cleared the Application for an Investigational New Drug (IND) ) from the company to its main candidate E-602. This authorization paves the way for Palleon’s first in class cancer immunotherapy which targets immunosuppressive sialoglycans to enter clinical trials.

Increase the initiatives of the main market and government players

Increased initiatives by major players and the government to help cancer patients are expected to drive the growth of the market during the forecast period. For example, in January 2021, The Lung Ambition Alliance, a global coalition with the bold ambition to eliminate lung cancer as a cause of death, initiated ‘The Initiatives in Lung Cancer Care (ILC2)’ programme. The program’s goal is to fund projects that drive measurable improvements across the entire patient journey, from early detection to palliative care or survival.

Global Cancer Immunotherapy Cross-sectional analysis of the market:

Within the Type of Therapy, the Monoclonal Antibody segment is expected to maintain a dominant position in the North America region during the forecast period owing to the increasing collaboration of key market players. For example, on March 16, 2022, Sanofi, a pharmaceutical company, announced a collaboration with Seagen Inc, a pharmaceutical company, to design, develop and commercialize Antibody-Drug Conjugates (ADCs) for up to three cancer targets. This collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies that are designed to deliver potent anti-cancer drugs to tumor cells by expressing a specific protein. Currently, Sanofi only has one ADC in development.

In the application segment, the breast cancer segment is expected to maintain a dominant position in the North American region due to the increasing prevalence of breast cancer in the region. For example, data published on May 10, 2022 by the National Cancer Institute, stated that in the US there were approximately 290,560 new cases of breast cancer in 2022.

Main developments:

In June 2020, Genmab, a pharmaceutical company, announced a collaboration with AbbVie Inc., a pharmaceutical company, to jointly develop and commercialize three of Genmab’s early-stage investigational bispecific antibody product candidates and enter into a breakthrough research collaboration for future differentiated antibody therapies for Cancer. The companies collaborated to develop Genmab’s next-generation bispecific antibody programs, epcoritamab DuoHexaBody-CD37 and DuoBody-CD3x5T4. This collaboration combined Genmab’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with AbbVie’s deep clinical experience, innovative antibody-drug conjugate (ADC) platform, and global commercial leadership in hematologic cancers.

In April 2021, the US Food and Drug Administration approved Opdivo, in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

In November 2020, Sanofi, a pharmaceutical company, announced the acquisition of Kiadis Pharma, a pharmaceutical company that specializes in cell-based immunotherapy products to treat cancer. The acquisition will give Sanofi access to Kiadis’ K-NK-cell platform, designed to make products available quickly and cost-effectively to a broad patient population across a wide range of indications. This will strengthen Sanofi’s product portfolio.

On September 9, 2022, Siemens Healthineers, a medical device company, announced partnerships with Indian Institute of Science (IISc), which is a research university, HealthCare Global Enterprises Ltd (HCG), a healthcare organization, and Narayana Health (NH), which is a multi-specialty private hospital. Siemens Healthineers will work with all three organizations in areas such as advancing cardiovascular care, improving the quality of cancer care for the community, and developing fellowship programs in the oncology space.

Key findings from the market:

The global cancer immunotherapy market is expected to exhibit a CAGR in 9.9% during the forecast period due to the increased prevalence of cancer. For example, according to data published in May 2022, the Canadian Cancer Society, which is Canada’s national cancer charity, estimated that 30,000 Canadians will be diagnosed with lung and bronchus cancer in 2022.

Among applications, the breast cancer segment is expected to hold a dominant position in the forecast period due to increased awareness initiatives by major market players. For example, on October 22, 2022, Urban Company, a technology-enabled home services company, joined the HCG Cancer Chain of Hospitals. As part of this initiative, HCG oncologists conducted breast self-examination workshops to create breast cancer awareness.

On an end-user basis, the hospital segment is expected to hold a dominant position during the forecast period due to the increase in the number of hospitals. For example, data published in January 2022 by the American Hospital Association stated that in the US there were approximately 6,093 hospitals in 2022.

Competitive scenario:

Major players operating in the global cancer immunotherapy market include Novartis AG, Merck & Co. Inc., F-Hoffmann La Roche, Eli Lilly and Company, Bayer AG, AstraZeneca, Astellas Pharma Inc., Amgen Inc., OSE Immunotherapeutics SA and Bristol-Myers Squibb Company

Buy this research report now @ https://www.coherentmarketinsights.com/insight/buy-now/5274

Market segmentation:

  • Global Cancer Immunotherapy Market by Type of Therapy:
    • Monoclonal Antibodies
    • cancer vaccines
    • Immunomodulators
    • Immune Checkpoint Inhibitors
    • Other types of therapy
  • Global Cancer Immunotherapy Market by Application:-
    • Prostate cancer
    • Breast cancer
    • Skin cancer
    • Lung cancer
    • Other Applications
  • Global Cancer Immunotherapy Market by End Users:
    • Hospitals and clinics
    • Cancer Research Centers
    • Other End Users
  • Global Cancer Immunotherapy Market by Geography:
    • North America
    • Latin America
      • by country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • by country
        • Germany
        • UK
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • by country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • middle East
      • by country
        • GCC
        • Israel
        • Rest of the Middle East
    • Africa
      • by region/country
        • South Africa
        • Central Africa
        • North Africa

Related market intelligence reports:

Biological Marketby product (monoclonal antibodies, vaccines, recombinant hormones/proteins, cell-based biologics, gene-based biologics and other products), by application (cancer, infectious diseases, autoimmune diseases and other applications) and by geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America) – Analysis of size, participation, prospects and opportunities, 2022 – 2030

Therapeutic and diagnostic market for pancreatic cancerby type (treatment (targeted therapies, chemotherapy, surgery and other treatments) and diagnoses (imaging, biopsy, endoscopic ultrasound and other diagnoses) and geography (North America, Europe, Asia Pacific, Middle East and Africa and South America) – Size, participation, perspective and opportunity analysis, 2022 – 2028

About Us:

Consistent market insights is a global consulting and market intelligence organization focused on helping our multitude of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with sales offices in the global financial capital in the US and sales consultants in the UK and Japan. Our customer base includes players from various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in delivering insights across multiple industries post-COVID-19 and continuing to deliver measurable and sustainable results for our clients.

Follow us: LinkedIn | twitter

Global Cancer Immunotherapy Market Will Exceed $216,792.7

Leave a Reply

Your email address will not be published.

Scroll to top